After a treatment breakthrough: A comparison of trial and population-based data for advanced testicular cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Neoplasms, Germ Cell and Embryonal
  • Testicular Neoplasms

abstract

  • Although most of the patients in the SEER series received cisplatin-based chemotherapy, this alone did not produce results equivalent to that in the MSKCC series. Since the patients were selected to be as diagnostically comparable as possible at baseline, remaining differences in survival may be due to adherence to a fixed regimen and level of dose-intensity, adequacy of diagnostic work-up, implementation of salvage therapies and debulking surgery, and unknown factors related to who is willing and able to travel to a tertiary care center for treatment. Whatever the reason for not achieving optimal results in the SEER series, the very modest survival improvements over the time period 1978 to 1984 indicates that the differences in outcome between the two series were basically stable over the study period.

publication date

  • February 1994

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 7509384

Additional Document Info

start page

  • 368

end page

  • 77

volume

  • 12

number

  • 2